Core Viewpoint - The article discusses Beijing Lideman Biochemical Co., Ltd.'s plan to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which is expected to enhance Lideman's competitive position in the IVD business sector, particularly in tuberculosis diagnosis and treatment [1][6]. Group 1: Acquisition Details - Lideman announced on July 30 that it is planning to acquire a majority stake in Xiansheng Xiangrui, which will become a subsidiary post-transaction [1]. - The funding for this acquisition will come from Lideman's own funds and bank loans, with the estimated cost for 70% of Xiansheng Xiangrui's shares being approximately 2.9323 billion yuan [10]. - The transaction is classified as a major asset restructuring under the regulations, and it does not involve issuing new shares or changing control of Lideman [1]. Group 2: Target Company Overview - Xiansheng Xiangrui operates in the biopharmaceutical manufacturing sector, focusing on in-vitro diagnostic reagents and human vaccines, with key products related to tuberculosis screening and treatment [3]. - The company was listed on the New Third Board in September 2022 and has been undergoing guidance for a potential listing on the Beijing Stock Exchange since 2023 [4][5]. - Xiansheng Xiangrui's revenue from 2020 to 2024 is projected to be stable, with figures of 390 million, 530 million, 639 million, 653 million, and 582 million yuan, and net profits of 95 million, 150 million, 128 million, 121 million, and 149 million yuan respectively [5]. Group 3: Lideman's Financial Performance - Lideman's financial performance has been volatile, with revenues from 2020 to 2024 reported as 472 million, 564 million, 706 million, 462 million, and 370 million yuan, and net profits fluctuating between losses and gains [8]. - The company's first-quarter report for 2025 indicated a revenue decline of 16.61% year-on-year, with a net loss of 1.2517 million yuan [8]. - The comparison shows that Xiansheng Xiangrui's net profit performance significantly exceeds that of Lideman, indicating a potential strategic move by Lideman to improve its financial situation through this acquisition [9][8].

Core Viewpoint - The company Lide Man is planning to acquire up to 70% of shares in Xiansheng Xiangrui, which will enhance its IVD business and overall competitiveness [1][4]. Group 1: Company Overview - Lide Man's stock price closed at 7.04 yuan with a total market value of 3.83 billion yuan as of July 31 [1]. - The company specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [5]. - Lide Man has experienced significant fluctuations in its financial performance, with revenues ranging from 3.7 billion yuan to 7.06 billion yuan from 2020 to 2024 [5]. Group 2: Target Company Overview - Xiansheng Xiangrui is engaged in the biopharmaceutical manufacturing sector, focusing on in vivo diagnostic reagents and human vaccines [2]. - The company was listed on the New Third Board in September 2022 and has been undergoing guidance for listing on the Beijing Stock Exchange since 2023 [3]. - Xiansheng Xiangrui's revenue from 2020 to 2024 shows a stable performance, with net profits ranging from 0.95 billion yuan to 1.49 billion yuan [3]. Group 3: Financial Implications of the Acquisition - The acquisition is expected to cost approximately 2.93 billion yuan for 70% of Xiansheng Xiangrui's shares based on its current market value [7]. - Lide Man's cash reserves were reported at 510 million yuan as of the first quarter of 2025, indicating a potential need for significant bank loans to finance the acquisition [7]. - The acquisition aims to improve Lide Man's financial situation, which has been characterized by alternating periods of profit and loss [6].

Core Viewpoint - The company Lideman is planning to acquire up to 70% of the shares of Beijing Xiansheng Xiangrui Biological Products Co., Ltd., which will allow Lideman to gain control over Xiansheng Xiangrui and enhance its competitive position in the IVD (in vitro diagnostics) sector, particularly in tuberculosis diagnosis and treatment [2][3][4]. Group 1: Transaction Details - Lideman has signed a framework agreement with shareholders of Xiansheng Xiangrui to acquire the shares through cash payment [3]. - The target company specializes in biopharmaceutical manufacturing, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [3][4]. - The funding for the acquisition will come from Lideman's own funds and bank loans, with the transaction price yet to be determined [3][4]. Group 2: Strategic Rationale - The acquisition is expected to add tuberculosis diagnosis and treatment capabilities to Lideman's existing IVD business, thereby strengthening its overall competitiveness and aligning with the interests of the company and its shareholders [4]. Group 3: Financial Performance - In the first quarter of 2025, Lideman reported revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, and a net loss attributable to shareholders of 1.25 million yuan [5]. - Despite recent financial challenges, Lideman's stock has seen a significant increase of over 44% since April 8, with the latest share price at 5.87 yuan, bringing the total market capitalization to 3.2 billion yuan [5].

Core Viewpoint - Lidman plans to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the company and enhance its IVD business segment, particularly in tuberculosis diagnosis and treatment [1][2]. Group 1: Transaction Details - The acquisition involves a cash purchase of shares from shareholders of Xiansheng Xiangrui, with no prior ownership of the target company by Lidman [1]. - The transaction is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][2]. - The funding for the acquisition will come from Lidman's own funds and bank acquisition loans, with the transaction price yet to be determined [2]. Group 2: Company and Industry Insights - Xiansheng Xiangrui operates in the biopharmaceutical manufacturing industry, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [1]. - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [2]. - The acquisition is expected to enhance Lidman's competitive edge by adding tuberculosis diagnosis and treatment capabilities, aligning with the interests of the company and its shareholders [2]. Group 3: Market Performance - Lidman's stock has seen a significant increase, with a cumulative rise of over 44% from April 8 to the present, reaching a closing price of 5.87 yuan per share and a total market capitalization of 3.2 billion yuan [3].

Group 1 - The core point of the article is that Lidman is planning to acquire up to 70% of the shares of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. in cash, which will give Lidman control over Xiansheng Xiangrui, making it a subsidiary [1][3] - The acquisition is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][3] - The target company operates in the biopharmaceutical manufacturing industry, focusing on in vitro diagnostic reagents and human vaccines, with key products related to tuberculosis screening and treatment [3] Group 2 - The funding for the acquisition will come from Lidman's own funds combined with bank acquisition loans, although the transaction price has not yet been determined [3] - The rationale behind the acquisition is to enhance Lidman's IVD business by adding tuberculosis diagnostic and treatment capabilities, which aligns with the company's strategic goals [4] - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [5]

Core Viewpoint - Lidman is planning to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which is expected to constitute a major asset restructuring [1][4]. Group 1: Acquisition Details - The acquisition will be funded through self-owned funds and bank merger loans, with Lidman not holding any shares in the target company prior to the transaction [4]. - Upon completion of the acquisition, Lidman will gain control of the target company, which will become a subsidiary [4]. - The investment framework agreement signed with the target company and its shareholders is only a preliminary agreement, with specific terms to be defined in formal agreements [4]. Group 2: Target Company Overview - The target company operates in the biopharmaceutical manufacturing industry, focusing on in vitro diagnostic reagents and human vaccines [4]. - Its main products include tuberculin purified protein derivative, bacillus Calmette-Guérin purified protein derivative, and specific cell immune response test kits for tuberculosis screening, diagnosis, treatment, and innovative vaccine development [4]. Group 3: Financial Performance - In 2024, Lidman reported a revenue of approximately 370 million yuan, a year-on-year decrease of 19.79%, with a net profit of -75.1 million yuan [6]. - The in vitro diagnostic reagent business remains the primary revenue source, generating about 297 million yuan, down 22.06%, accounting for 80.29% of total revenue [6]. - The first quarter of 2025 saw revenues of approximately 78.9 million yuan, a year-on-year decline of 16.61%, with a net profit of -1.25 million yuan [6]. Group 4: Market Position - As of July 30, Lidman's stock price was 5.87 yuan per share, with a market capitalization of 3.2 billion yuan [7].

Core Viewpoint - Company is planning to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the target company, which will become a subsidiary after the transaction is completed [1] Group 1: Transaction Details - The funding for the acquisition will come from the company's own funds and bank merger loans [1] - Prior to the transaction, the company did not hold any shares in the target company [1] - The investment framework agreement has been signed with the target company and its shareholders [1] Group 2: Target Company Overview - The target company operates in the biopharmaceutical manufacturing industry (C2761) [1] - It specializes in in vitro diagnostic reagents and human vaccines, with key products including purified protein derivative for tuberculosis and specific immune response detection kits [1] - The main applications of the target company's products are in tuberculosis screening, diagnosis, treatment, and innovative vaccine development [1] Group 3: Strategic Implications - Upon completion of the acquisition, the company's IVD (in vitro diagnostics) business segment will expand to include tuberculosis diagnostic screening and integrated treatment business, as well as innovative vaccine initiatives [1]

公告显示，目标公司所处行业为生物药品制造(C2761)，是一家主要从事体内诊断试剂及人用疫苗的企 业，主要产品为结核菌素纯蛋白衍生物，卡介菌纯蛋白衍生物，结核分枝杆菌特异性细胞免疫反应检测 试剂盒，主要应用于结核筛查、诊断、治疗及创新疫苗领域。本次交易完成后，公司的IVD业务板块 中，将新增结核诊断筛查业务，并拓展结核治疗一体化业务及创新疫苗业务。 利德曼（300289）(300289.SZ)公告，公司正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有 限公司(本次交易目标公司)部分股东持有的目标公司合计不超过70%的股份。公司本次交易资金来源拟 运用自有资金并结合银行并购贷款等方式筹集资金。本次交易前，公司未持有目标公司的股份;本次交 易完成后，公司将取得目标公司控制权，目标公司将成为公司的控股子公司。 日前，公司与目标公司、目标公司股东上海百家汇投资管理有限公司、海南先声百家汇科技发展有限公 司、南京百佳瑞企业管理咨询合伙企业(有限合伙)签署《投资框架协议》。 ...

北京商报讯(记者丁宁)7月30日晚间，利德曼（300289）发布公告称，公司正在筹划以支付现金方式收 购北京先声祥瑞生物制品股份有限公司(以下简称"先声祥瑞")部分股东持有的目标公司合计不超过70% 的股份。公司本次交易资金来源拟运用自有资金并结合银行并购贷款等方式筹集资金。 公告显示，先声祥瑞所处行业为生物药品制造，是一家主要从事体内诊断试剂及人用疫苗的企业，主要 产品为结核菌素纯蛋白衍生物，卡介菌纯蛋白衍生物，结核分枝杆菌特异性细胞免疫反应检测试剂盒， 主要应用于结核筛查、诊断、治疗及创新疫苗领域。 利德曼表示，本次交易完成后，公司的IVD业务板块中，将新增结核诊断筛查业务，并拓展结核治疗一 体化业务及创新疫苗业务，有利于加强公司综合竞争力，符合公司及股东利益。 ...

利德曼(300289.SZ)公告称，公司正在筹划以支付现金方式收购北京 先声祥瑞生物制品股份有限公司部 分股东持有的目标公司合计不超过70%的股份。公司本次交易资金来源拟运用自有资金并结合银行并购 贷款等方式筹集资金。目标公司所处行业为生物药品制造（C2761），是一家主要从事体内诊断试剂及 人用疫苗的企业，主要产品为结核菌素纯蛋白衍生物，卡介菌纯蛋白衍生物，结核分枝杆菌特异性 细 胞免疫反应检测试剂盒，主要应用于结核筛查、诊断、治疗及创新 疫苗领域。本次交易完成后，公司 的IVD业务板块中，将新增结核诊断筛查业务，并拓展结核治疗一体化业务及创新疫苗业务。 ...